BACKGROUND How statins alter the natural course of coronary atherosclerosis with compositional changes remains
Anatomically comparable distal and proximal fiduciary points (such as side branches, calcium, or other imaging landmarks) were used for evaluating identical segments using multiple modalities at baseline and at follow-up. After clinical screening (Online Table 1 
Park et al.
A P R I L 1 9 , 2 0 1 6 : 1 7 7 2 -8 3 The investigators were blinded to the assigned statin treatment and to whether a study was acquired at baseline or at follow-up. When there was discordance between the observers, a consensus reading was obtained. was located at baseline (index lesion).
The pre-specified primary efficacy endpoint was the change in VH-defined percent compositional volume within the target segment from baseline to follow-up. The pre-specified secondary endpoint was the change in percent compositional volume comparing the rosuvastatin 40-mg versus 10-mg groups.
The investigators were blinded to the assigned statin treatment and also to whether a study was at baseline or follow-up. When there was discordance between the observers, including plaque type classification, a consensus reading was obtained. 
CENTRAL ILLUSTRATION Continued
A P R I L 1 9 , 2 0 1 6 : 1 7 7 2 -8 3
Statin Effect on Plaque Modification rupture, and thrombus were defined as previously described (17) (18) (19) (20) NC ¼ necrotic core; TAV ¼ normalized total atheroma volume; VH-TCFA ¼ virtual histology-defined thin-cap fibroatheroma.
Statin Effect on Plaque Modification
A P R I L 1 9 , 2 0 1 6 : 1 7 7 2 -8 3 analysis in Figure 1 were on the basis of the linear Lesion location was the left anterior descending artery in 88 patients (39%), the right coronary artery in 94 (40%), and the left circumflex artery in 43 (19%).
Between baseline and 1-year follow-up, there was an As the secondary efficacy parameter, the change in VH-defined percent compositional volume within the target segment was not significantly different between the rosuvastatin 40-and 10-mg groups ( Table 3) .
Although statin-naïve patients (vs. patients with a history of stain exposure before admission) showed a greater decrease in LDL cholesterol levels, there was no significant difference in the changes in percent NC 
A P R I L 1 9 , 2 0 1 6 : 1 7 7 2 -8 3 volume, normalized TAV, and PAV between the 2 groups (Online Table 3 ). Table 4 summarizes subgroup-specific effects of rosuvastatin on the changes in plaque volume and composition, according to MLA #4.0 mm 2 , plaque burden $70%, and the presence of VH-TCFA. The effect of rosuvastatin was shown according to angiographic diameter stenosis $50% (Online Table 4 ). Tables 1 and 2 . Values are mean AE SE, unless otherwise indicated. *p < 0.05 using nonparametric Mann-Whitney U test. †p < 0.05 using nonparametric Mann-Whitney U test (with Bonferroni method for multiplicity correction). Tables 2 and 3 . to À0.10; p < 0.001).
Abbreviations as in
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EFFECT OF HIGH-VERSUS MODERATE-DOSE
STATIN. Online Table 5 shows baseline and follow-up grayscale and VH-IVUS data in patients treated with rosuvastatin 40 and 10 mg. Even though rosuvastatin 40 mg was associated with a greater reduction in total cholesterol, LDL cholesterol, and the low-to high-density lipoprotein ratio compared with rosuvastatin 10 mg, the changes in atheroma volume and composition were not significantly different between the 2 dosing groups (all p > 0.05) (Online Table 6 ). Between rosuvastatin 40 mg versus 10 mg, there were no significant differences in the frequency of normalized TAV reduction (69.1% vs. 63. Nonculprit-related major adverse cardiac events occurred in 8 (3.6%) patients (7 target lesion revascularizations and 1 myocardial infarction). There Abbreviations as in Tables 2 and 3 . 
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